Accelerating drug development for neuroblastoma: Summary of the
Second Neuroblastoma Drug Development Strategy forum from
Innovative Therapies for Children with Cancer and International
Society of Paediatric Oncology Europe Neuroblastoma

J 2020

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

MORENO, L.; G. BARONE; S. G. DUBOIS; J. MOLENAAR; M. FISCHER et al.

Základní údaje

Originální název

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma

Autoři

Vydání

European Journal of Cancer, Oxford, Elsevier Science Inc. 2020, 0959-8049

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.162

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116258

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Neuroblastoma; Drug development; Phase I; Preclinical testing; Clinical trials; MYCN; Epigenetics

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 8. 2020 13:10, Mgr. Tereza Miškechová

Anotace

V originále

Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to accelerate the development of new drugs for neuroblastoma. Advances have occurred, with eight of nine high-priority targets being evaluated in paediatric trials including anaplastic lymphoma kinase inhibitors being investigated in front-line, but significant challenges remain. This article reports the conclusions of the second NDDS forum, which expanded across the Atlantic to further develop the initiative. Pre-clinical and clinical data for 40 genetic targets and mechanisms of action were prioritised and drugs were identified for early-phase trials. Strategies to develop drugs targeting TERT, telomere maintenance, ATRX, alternative lengthening of telomeres (ALT), BRIP1 and RRM2 as well as direct targeting of MYCN are high priority and should be championed for drug discovery. Promising pre-clinical data suggest that targeting of ALT by ATM or PARP inhibition may be potential strategies. Drugs targeting CDK2/9, CDK7, ATR and telomere maintenance should enter paediatric clinical development rapidly. Optimising the response to anti-GD2 by combinations with chemotherapy, targeted agents and other immunological targets are crucial. Delivering this strategy in the face of small patient cohorts, genomically defined subpopulations and a large number of permutations of combination trials, demands even greater international collaboration. In conclusion, the NDDS provides an internationally agreed, biologically driven selection of prioritised genetic targets and drugs. Improvements in the strategy for conducting trials in neuroblastoma will accelerate bringing these new drugs more rapidly to front-line therapy. (C) 2020 Elsevier Ltd. All rights reserved.

Citovat

MORENO, L.; G. BARONE; S. G. DUBOIS; J. MOLENAAR; M. FISCHER; J. SCHULTE; A. EGGERT; G. SCHLEIERMACHER; F. SPELEMAN; L. CHESLER; B. GEOERGER; M. D. HOGARTY; M. S. IRWIN; N. BIRD; G. B. BLANCHARD; S. BUCKLAND; H. CARON; S. DAVIS; B. DE WILDE; H. E. DEUBZER; E. DOLMAN; M. EILERS; R. E. GEORGE; S. GEORGE; Jaroslav ŠTĚRBA; J. M. MARIS; L. MARSHALL; M. MERCHANT; P. MORTIMER; C. OWENS; A. PHILPOTT; E. POON; J. W. SHAY; R. TONELLI; D. VALTEAU-COUANET; G. VASSAL; J. R. PARK a A. D. J. PEARSON. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer. Oxford: Elsevier Science Inc., 2020, roč. 136, SEP 2020, s. 52-68. ISSN 0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2020.05.010.

@article{1674867,
   author = {Moreno, L. and Barone, G. and DuBois, S. G. and Molenaar, J. and Fischer, M. and Schulte, J. and Eggert, A. and Schleiermacher, G. and Speleman, F. and Chesler, L. and Geoerger, B. and Hogarty, M. D. and Irwin, M. S. and Bird, N. and Blanchard, G. B. and Buckland, S. and Caron, H. and Davis, S. and De Wilde, B. and Deubzer, H. E. and Dolman, E. and Eilers, M. and George, R. E. and George, S. and Štěrba, Jaroslav and Maris, J. M. and Marshall, L. and Merchant, M. and Mortimer, P. and Owens, C. and Philpott, A. and Poon, E. and Shay, J. W. and Tonelli, R. and ValteauandCouanet, D. and Vassal, G. and Park, J. R. and Pearson, A. D. J.},
   article_location = {Oxford},
   article_number = {SEP 2020},
   doi = {https://doi.org/10.1016/j.ejca.2020.05.010},
   keywords = {Neuroblastoma; Drug development; Phase I; Preclinical testing; Clinical trials; MYCN; Epigenetics},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma},
   url = {https://www.sciencedirect.com/science/article/pii/S0959804920302768?via%3Dihub},
   volume = {136},
   year = {2020}
}

TY  - JOUR
ID  - 1674867
AU  - Moreno, L. - Barone, G. - DuBois, S. G. - Molenaar, J. - Fischer, M. - Schulte, J. - Eggert, A. - Schleiermacher, G. - Speleman, F. - Chesler, L. - Geoerger, B. - Hogarty, M. D. - Irwin, M. S. - Bird, N. - Blanchard, G. B. - Buckland, S. - Caron, H. - Davis, S. - De Wilde, B. - Deubzer, H. E. - Dolman, E. - Eilers, M. - George, R. E. - George, S. - Štěrba, Jaroslav - Maris, J. M. - Marshall, L. - Merchant, M. - Mortimer, P. - Owens, C. - Philpott, A. - Poon, E. - Shay, J. W. - Tonelli, R. - Valteau-Couanet, D. - Vassal, G. - Park, J. R. - Pearson, A. D. J.
PY  - 2020
TI  - Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
JF  - European Journal of Cancer
VL  - 136
IS  - SEP 2020
SP  - 52-68
EP  - 52-68
PB  - Elsevier Science Inc.
SN  - 09598049
KW  - Neuroblastoma
KW  - Drug development
KW  - Phase I
KW  - Preclinical testing
KW  - Clinical trials
KW  - MYCN
KW  - Epigenetics
UR  - https://www.sciencedirect.com/science/article/pii/S0959804920302768?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0959804920302768?via%3Dihub
N2  - Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to accelerate the development of new drugs for neuroblastoma. Advances have occurred, with eight of nine high-priority targets being evaluated in paediatric trials including anaplastic lymphoma kinase inhibitors being investigated in front-line, but significant challenges remain. This article reports the conclusions of the second NDDS forum, which expanded across the Atlantic to further develop the initiative. Pre-clinical and clinical data for 40 genetic targets and mechanisms of action were prioritised and drugs were identified for early-phase trials. Strategies to develop drugs targeting TERT, telomere maintenance, ATRX, alternative lengthening of telomeres (ALT), BRIP1 and RRM2 as well as direct targeting of MYCN are high priority and should be championed for drug discovery. Promising pre-clinical data suggest that targeting of ALT by ATM or PARP inhibition may be potential strategies. Drugs targeting CDK2/9, CDK7, ATR and telomere maintenance should enter paediatric clinical development rapidly. Optimising the response to anti-GD2 by combinations with chemotherapy, targeted agents and other immunological targets are crucial. Delivering this strategy in the face of small patient cohorts, genomically defined subpopulations and a large number of permutations of combination trials, demands even greater international collaboration. In conclusion, the NDDS provides an internationally agreed, biologically driven selection of prioritised genetic targets and drugs. Improvements in the strategy for conducting trials in neuroblastoma will accelerate bringing these new drugs more rapidly to front-line therapy. (C) 2020 Elsevier Ltd. All rights reserved.
ER  -

MORENO, L.; G. BARONE; S. G. DUBOIS; J. MOLENAAR; M. FISCHER; J. SCHULTE; A. EGGERT; G. SCHLEIERMACHER; F. SPELEMAN; L. CHESLER; B. GEOERGER; M. D. HOGARTY; M. S. IRWIN; N. BIRD; G. B. BLANCHARD; S. BUCKLAND; H. CARON; S. DAVIS; B. DE WILDE; H. E. DEUBZER; E. DOLMAN; M. EILERS; R. E. GEORGE; S. GEORGE; Jaroslav ŠTĚRBA; J. M. MARIS; L. MARSHALL; M. MERCHANT; P. MORTIMER; C. OWENS; A. PHILPOTT; E. POON; J. W. SHAY; R. TONELLI; D. VALTEAU-COUANET; G. VASSAL; J. R. PARK a A. D. J. PEARSON. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2020, roč.~136, SEP 2020, s.~52-68. ISSN~0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2020.05.010.

Přehled o publikaci